Practical aspects of the use of amiodarone

P Puech1

  • 1Department of Cardiology, Hôpital Saint Eloi, Montpellier, France.

Drugs
|January 1, 1991
PubMed

Insights

Amiodarone, a potent antiarrhythmic drug, effectively treats cardiac arrhythmias but carries risks of side effects. Optimizing its use involves loading doses and considering interactions with other medications.

Area of Science:

  • Pharmacology
  • Cardiology
  • Clinical Therapeutics

Background:

  • Amiodarone is a Class III antiarrhythmic agent with sympatholytic effects.
  • It prolongs cardiac refractory periods and depresses sinus and AV nodal function.
  • Its efficacy in treating various arrhythmias is recognized, but side effects limit its use.

Purpose of the Study:

  • To summarize the pharmacological properties and clinical applications of amiodarone.
  • To discuss strategies for optimizing amiodarone therapy and minimizing side effects.
  • To highlight potential drug interactions and considerations for combination therapy.

Main Methods:

  • Review of amiodarone's mechanism of action and pharmacokinetic profile.
  • Analysis of clinical data regarding efficacy and side effect profiles.
  • Examination of drug interaction studies and clinical guidelines.

Main Results:

  • Amiodarone effectively manages diverse cardiac arrhythmias.
  • Extracardiac side effects are dose and duration-dependent.
  • Oral loading doses can expedite therapeutic blood concentrations.
  • Slow elimination allows for intermittent dosing in long-term therapy.
  • Significant pharmacokinetic and pharmacodynamic interactions exist with other drugs.

Conclusions:

  • Amiodarone is a valuable antiarrhythmic, but careful management is crucial.
  • Optimizing dosage and duration can mitigate side effect risks.
  • Awareness of drug interactions is essential for safe and effective co-administration.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...